CleftGeneDB-Search

Gene: ELAVL1

Basic information

Tag	Content
Uniprot ID	Q15717; B4DVB8; Q53XN6; Q9BTT1;
Entrez ID	1994
Genbank protein ID	AAH03376.1; AAP88795.1; EAW68949.1; BAG62630.1; AAB41913.1;
Genbank nucleotide ID	NM_001419.2
Ensembl protein ID	ENSP00000385269; ENSP00000472197;
Ensembl nucleotide ID	ENSG00000066044
Gene name	ELAV-like protein 1
Gene symbol	ELAVL1
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability (PubMed:14517288, PubMed:18285462, PubMed:31358969). Involved in embryonic stem cells (ESCs) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESCs differentiation (By similarity). Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:8626503, PubMed:17632515, PubMed:18285462, PubMed:23519412, PubMed:14731398). Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'-UUUU[AG]UUU-3' motif in vitro (PubMed:8626503). With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA (By similarity). Increases the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR (PubMed:29180010).
Sequence	MSNGYEDHMA EDCRGDIGRT NLIVNYLPQN MTQDELRSLF SSIGEVESAK LIRDKVAGHS 60 LGYGFVNYVT AKDAERAINT LNGLRLQSKT IKVSYARPSS EVIKDANLYI SGLPRTMTQK 120 DVEDMFSRFG RIINSRVLVD QTTGLSRGVA FIRFDKRSEA EEAITSFNGH KPPGSSEPIT 180 VKFAANPNQN KNVALLSQLY HSPARRFGGP VHHQAQRFRF SPMGVDHMSG LSGVNVPGNA 240 SSGWCIFIYN LGQDADEGIL WQMFGPFGAV TNVKVIRDFN TNKCKGFGFV TMTNYEEAAM 300 AIASLNGYRL GDKILQVSFK TNKSHK 326

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
3HI9
4ED5
4EGL
4FXV
5SZW
6G2K
6GC5
6GD1
6GD2
6GD3
4ED5
4FXV
5SZW

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	ELAVL1	617316	Q3ZCE2		Bos taurus	Prediction	More>>
1:1 ortholog	ELAVL1	102173732	A0A452EKQ9		Capra hircus	Prediction	More>>
1:1 ortholog	ELAVL1		F6VTW3		Equus caballus	Prediction	More>>
1:1 ortholog	ELAVL1	1994	Q15717		Homo sapiens	Prediction	More>>
1:1 ortholog	Elavl1	15568	P70372	CPO	Mus musculus	Publication	More>>
1:1 ortholog	ELAVL1	743010	K7D3Q8		Pan troglodytes	Prediction	More>>
1:1 ortholog	ELAVL1	100337681	D3K5N7		Sus scrofa	Prediction	More>>
1:1 ortholog	Elavl1	363854	B5DF91		Rattus norvegicus	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs767314853	p.Glu6Gly	missense variant	-	NC_000019.10:g.7991799T>C	ExAC,gnomAD
rs754511831	p.His8Leu	missense variant	-	NC_000019.10:g.7991793T>A	ExAC,gnomAD
rs754511831	p.His8Arg	missense variant	-	NC_000019.10:g.7991793T>C	ExAC,gnomAD
rs751134984	p.Met9Val	missense variant	-	NC_000019.10:g.7991791T>C	ExAC,TOPMed,gnomAD
rs368659692	p.Glu11Lys	missense variant	-	NC_000019.10:g.7991785C>T	ESP,ExAC,gnomAD
rs368659692	p.Glu11Ter	stop gained	-	NC_000019.10:g.7991785C>A	ESP,ExAC,gnomAD
rs1419502367	p.Cys13Arg	missense variant	-	NC_000019.10:g.7991779A>G	TOPMed
rs773607076	p.Arg14Lys	missense variant	-	NC_000019.10:g.7991775C>T	ExAC,gnomAD
rs765588626	p.Gly15Ser	missense variant	-	NC_000019.10:g.7991773C>T	ExAC,gnomAD
rs183919265	p.Asp16Tyr	missense variant	-	NC_000019.10:g.7991770C>A	1000Genomes
rs762197301	p.Ile17Val	missense variant	-	NC_000019.10:g.7991767T>C	ExAC,gnomAD
rs370966971	p.Ile17Met	missense variant	-	NC_000019.10:g.7991765G>C	ESP,ExAC,TOPMed,gnomAD
rs941493606	p.Gly18Arg	missense variant	-	NC_000019.10:g.7991764C>T	TOPMed,gnomAD
rs1298720420	p.Val24Ile	missense variant	-	NC_000019.10:g.7991746C>T	TOPMed
rs749196794	p.Ser38Arg	missense variant	-	NC_000019.10:g.7991704T>G	ExAC,gnomAD
rs1294906748	p.Ser42Asn	missense variant	-	NC_000019.10:g.7991691C>T	TOPMed
rs1047630892	p.Ser42Gly	missense variant	-	NC_000019.10:g.7991692T>C	TOPMed
rs755938476	p.Ala49Ser	missense variant	-	NC_000019.10:g.7991671C>A	ExAC,gnomAD
rs1356330378	p.Ile52Val	missense variant	-	NC_000019.10:g.7991662T>C	TOPMed
rs748009879	p.Arg53Trp	missense variant	-	NC_000019.10:g.7991659G>A	ExAC,gnomAD
rs757894457	p.Val69Met	missense variant	-	NC_000019.10:g.7981154C>T	ExAC,gnomAD
rs749959468	p.Thr70Ser	missense variant	-	NC_000019.10:g.7981150G>C	ExAC,TOPMed,gnomAD
rs749959468	p.Thr70Ile	missense variant	-	NC_000019.10:g.7981150G>A	ExAC,TOPMed,gnomAD
rs1002242021	p.Ala71Thr	missense variant	-	NC_000019.10:g.7981148C>T	TOPMed,gnomAD
rs757692680	p.Ala71Val	missense variant	-	NC_000019.10:g.7981147G>A	ExAC,gnomAD
rs1194079610	p.Lys72Arg	missense variant	-	NC_000019.10:g.7981144T>C	gnomAD
rs1265243454	p.Glu75Gly	missense variant	-	NC_000019.10:g.7981135T>C	gnomAD
rs936268706	p.Ala77Ser	missense variant	-	NC_000019.10:g.7981130C>A	TOPMed
rs752929356	p.Thr80Met	missense variant	-	NC_000019.10:g.7981120G>A	ExAC,gnomAD
rs1282019819	p.Ala106Thr	missense variant	-	NC_000019.10:g.7973839C>T	gnomAD
rs748842783	p.Arg115Gln	missense variant	-	NC_000019.10:g.7973811C>T	ExAC,gnomAD
rs1353862599	p.Val122Ile	missense variant	-	NC_000019.10:g.7973791C>T	TOPMed,gnomAD
rs756651324	p.Met125Leu	missense variant	-	NC_000019.10:g.7973782T>A	ExAC,gnomAD
rs1392143313	p.Arg128Gly	missense variant	-	NC_000019.10:g.7973773G>C	TOPMed
rs140179606	p.Arg128Gln	missense variant	-	NC_000019.10:g.7973772C>T	ESP,ExAC,TOPMed,gnomAD
rs1156860701	p.Arg131Trp	missense variant	-	NC_000019.10:g.7973764G>A	TOPMed,gnomAD
rs201280427	p.Arg131Gln	missense variant	-	NC_000019.10:g.7973763C>T	ExAC,TOPMed,gnomAD
rs1160077839	p.Ser135Leu	missense variant	-	NC_000019.10:g.7973751G>A	TOPMed,gnomAD
rs759364043	p.Val139Met	missense variant	-	NC_000019.10:g.7973740C>T	ExAC,gnomAD
rs1481181693	p.Thr142Ser	missense variant	-	NC_000019.10:g.7973730G>C	TOPMed
rs1462127678	p.Ile152Val	missense variant	-	NC_000019.10:g.7967767T>C	gnomAD
rs761216666	p.Ser158Leu	missense variant	-	NC_000019.10:g.7967748G>A	ExAC,gnomAD
rs768294547	p.Asn168Ser	missense variant	-	NC_000019.10:g.7967718T>C	ExAC
rs1418897226	p.Pro172Thr	missense variant	-	NC_000019.10:g.7967707G>T	gnomAD
rs376219740	p.Pro173Ser	missense variant	-	NC_000019.10:g.7967704G>A	ESP,ExAC,TOPMed,gnomAD
rs1481044004	p.Glu177Asp	missense variant	-	NC_000019.10:g.7967690C>A	gnomAD
rs1350103997	p.Pro187His	missense variant	-	NC_000019.10:g.7967661G>T	gnomAD
rs746289699	p.Val193Met	missense variant	-	NC_000019.10:g.7967644C>T	ExAC,gnomAD
rs370407808	p.Ala204Val	missense variant	-	NC_000019.10:g.7967610G>A	ESP,ExAC,TOPMed,gnomAD
rs756212952	p.Ala204Ser	missense variant	-	NC_000019.10:g.7967611C>A	ExAC,gnomAD
rs1284436080	p.Arg205Gln	missense variant	-	NC_000019.10:g.7967607C>T	TOPMed
rs377051094	p.Phe207Leu	missense variant	-	NC_000019.10:g.7967600G>C	ESP,ExAC,TOPMed,gnomAD
rs750293457	p.Val211Ile	missense variant	-	NC_000019.10:g.7967590C>T	ExAC,TOPMed,gnomAD
rs138823708	p.Ala215Pro	missense variant	-	NC_000019.10:g.7967578C>G	ESP,ExAC,TOPMed,gnomAD
rs756868982	p.Ala215Val	missense variant	-	NC_000019.10:g.7967577G>A	ExAC,gnomAD
rs763270784	p.Val225Ile	missense variant	-	NC_000019.10:g.7963791C>T	ExAC,TOPMed,gnomAD
rs1463328008	p.His227Pro	missense variant	-	NC_000019.10:g.7963784T>G	gnomAD
rs1233395072	p.Met228Leu	missense variant	-	NC_000019.10:g.7963782T>A	TOPMed
rs1179916551	p.Ser232Ala	missense variant	-	NC_000019.10:g.7963770A>C	TOPMed
rs776625986	p.Val234Ile	missense variant	-	NC_000019.10:g.7963764C>T	ExAC,TOPMed,gnomAD
rs768632820	p.Asn235Ser	missense variant	-	NC_000019.10:g.7963760T>C	ExAC,TOPMed,gnomAD
rs1215396504	p.Val236Gly	missense variant	-	NC_000019.10:g.7963757A>C	gnomAD
rs1468733287	p.Pro237Ala	missense variant	-	NC_000019.10:g.7963755G>C	gnomAD
rs1329545368	p.Asn239Ser	missense variant	-	NC_000019.10:g.7963748T>C	TOPMed
rs770736507	p.Ala240Thr	missense variant	-	NC_000019.10:g.7963746C>T	ExAC,TOPMed,gnomAD
rs1232923071	p.Ser241Ala	missense variant	-	NC_000019.10:g.7963743A>C	gnomAD
rs752407235	p.Cys245Gly	missense variant	-	NC_000019.10:g.7963731A>C	ExAC,gnomAD
rs1398738001	p.Asp254Ala	missense variant	-	NC_000019.10:g.7963703T>G	gnomAD
rs754481468	p.Ala255Val	missense variant	-	NC_000019.10:g.7963700G>A	ExAC,gnomAD
rs148254612	p.Asp256Asn	missense variant	-	NC_000019.10:g.7963698C>T	ESP,ExAC,TOPMed,gnomAD
rs1186504207	p.Asn280Thr	missense variant	-	NC_000019.10:g.7963625T>G	TOPMed
rs774331648	p.Thr281Ile	missense variant	-	NC_000019.10:g.7963622G>A	ExAC,gnomAD
rs770836572	p.Gly286Glu	missense variant	-	NC_000019.10:g.7963607C>T	ExAC,TOPMed,gnomAD
rs769730671	p.Glu297Asp	missense variant	-	NC_000019.10:g.7963573T>G	ExAC,TOPMed,gnomAD
rs894992560	p.Ala299Thr	missense variant	-	NC_000019.10:g.7963569C>T	gnomAD
rs894992560	p.Ala299Ser	missense variant	-	NC_000019.10:g.7963569C>A	gnomAD
rs1376533736	p.Ala303Gly	missense variant	-	NC_000019.10:g.7963556G>C	TOPMed
rs1417780516	p.Tyr308Cys	missense variant	-	NC_000019.10:g.7963541T>C	gnomAD
rs780607258	p.Arg309Cys	missense variant	-	NC_000019.10:g.7963539G>A	ExAC,gnomAD
rs1414902866	p.Arg309His	missense variant	-	NC_000019.10:g.7963538C>T	gnomAD
rs1414902866	p.Arg309Leu	missense variant	-	NC_000019.10:g.7963538C>A	gnomAD
rs1471027091	p.Asn322Ser	missense variant	-	NC_000019.10:g.7963499T>C	gnomAD
rs1193306049	p.Asn322Lys	missense variant	-	NC_000019.10:g.7963498G>C	gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001430	Adenoma	group	LHGDN
C0002736	Amyotrophic Lateral Sclerosis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE;LHGDN
C0004153	Atherosclerosis	disease	LHGDN
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	LHGDN
C0009375	Colonic Neoplasms	group	LHGDN
C0010346	Crohn Disease	disease	BEFREE
C0011311	Dengue Fever	disease	BEFREE
C0014175	Endometriosis	disease	CTD_human
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0020615	Hypoglycemia	disease	BEFREE
C0022578	Keratoconus	disease	BEFREE
C0024141	Lupus Erythematosus, Systemic	disease	LHGDN
C0025007	Measles	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE;LHGDN
C0025500	Mesothelioma	disease	LHGDN
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0029408	Degenerative polyarthritis	disease	LHGDN
C0029925	Ovarian Carcinoma	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0038356	Stomach Neoplasms	group	LHGDN
C0085648	Synovial Cyst	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206752	Alphavirus Infections	group	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0221273	Juvenile polyp	disease	BEFREE
C0269102	Endometrioma	disease	CTD_human
C0338508	Optic Atrophy, Autosomal Dominant	disease	BEFREE
C0345893	Juvenile polyposis syndrome	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1258666	Myxoid cyst	disease	BEFREE
C1261473	Sarcoma	group	LHGDN
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1510885	Angiogenic Switch	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C2062416	Sindbis virus infection	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C3839280	High grade serous carcinoma	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0003723	RNA binding	IDA
GO:0003723	RNA binding	HDA
GO:0003725	double-stranded RNA binding	IDA
GO:0003729	mRNA binding	TAS
GO:0003730	mRNA 3'-UTR binding	ISS
GO:0003730	mRNA 3'-UTR binding	IDA
GO:0005515	protein binding	IPI
GO:0017091	AU-rich element binding	IDA
GO:0019901	protein kinase binding	IPI
GO:0035198	miRNA binding	IDA
GO:0035925	mRNA 3'-UTR AU-rich region binding	IDA
GO:0042803	protein homodimerization activity	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000398	mRNA splicing, via spliceosome	TAS
GO:0006606	protein import into nucleus	IEA
GO:0043488	regulation of mRNA stability	TAS
GO:0045727	positive regulation of translation	IDA
GO:0048255	mRNA stabilization	IMP
GO:0048255	mRNA stabilization	IDA
GO:0051260	protein homooligomerization	IDA
GO:0060965	negative regulation of gene silencing by miRNA	IMP
GO:0060965	negative regulation of gene silencing by miRNA	IGI
GO:0070935	3'-UTR-mediated mRNA stabilization	IDA
GO:0070935	3'-UTR-mediated mRNA stabilization	IMP
GO:2000036	regulation of stem cell population maintenance	ISS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	IDA
GO:0005654	nucleoplasm	TAS
GO:0005737	cytoplasm	IDA
GO:0005783	endoplasmic reticulum	IEA
GO:0005829	cytosol	IDA
GO:0005829	cytosol	TAS
GO:0010494	cytoplasmic stress granule	ISS
GO:0016020	membrane	HDA
GO:0098794	postsynapse	IEA
GO:0098978	glutamatergic synapse	IEA
GO:1990904	ribonucleoprotein complex	ISS

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-450520	HuR (ELAVL1) binds and stabilizes mRNA	TAS
R-HSA-450531	Regulation of mRNA stability by proteins that bind AU-rich elements	TAS
R-HSA-72163	mRNA Splicing - Major Pathway	TAS
R-HSA-72172	mRNA Splicing	TAS
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA	TAS
R-HSA-8953854	Metabolism of RNA	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C550703	1,5-bis(2-bromophenyl)penta-1,4-dien-3-one	1,5-bis(2-bromophenyl)penta-1,4-dien-3-one affects the localization of ELAVL1 protein	20606309
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of ELAVL1 protein	26558463
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ELAVL1 mRNA	20453058
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ELAVL1 mRNA	19114083
C012796	2-butenal	2-butenal results in decreased expression of ELAVL1 mRNA	20471460
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane affects the expression of ELAVL1 mRNA	18648102
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELAVL1 mRNA	27188386
C029370	4-toluidine	4-toluidine results in decreased expression of ELAVL1 mRNA	27638505
C012606	4-vinyl-1-cyclohexene dioxide	4-vinyl-1-cyclohexene dioxide affects the expression of ELAVL1 mRNA	20829426
C496492	abrine	abrine results in decreased expression of ELAVL1 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of ELAVL1 mRNA	22230336
D000082	Acetaminophen	Acetaminophen affects the expression of ELAVL1 mRNA	17562736
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA]	22003189
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of ELAVL1 intron	30157460
C031143	AICA ribonucleotide	AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]	12730239
C031143	AICA ribonucleotide	AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR]	12730239
C031143	AICA ribonucleotide	AICA ribonucleotide results in decreased localization of ELAVL1 protein	12730239
D000968	Antimycin A	Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]	12730239
D000968	Antimycin A	Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR]	12730239
D000968	Antimycin A	Antimycin A results in decreased localization of ELAVL1 protein	12730239
C050510	arsenic trichloride	arsenic trichloride promotes the reaction [ELAVL1 protein binds to GADD45A mRNA]	16421274
D000077237	Arsenic Trioxide	Arsenic Trioxide promotes the reaction [ELAVL1 protein binds to TGIF1 promoter]	21649584
D000077237	Arsenic Trioxide	[Arsenic Trioxide promotes the reaction [ELAVL1 protein binds to TGIF1 promoter]] which results in decreased degradation of TGIF1 promoter	21649584
D001280	Atrazine	Atrazine results in decreased expression of ELAVL1 mRNA	22378314
D001507	Beclomethasone	Beclomethasone results in increased expression of ELAVL1 mRNA	23656298
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the methylation of ELAVL1 intron	30157460
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ELAVL1 mRNA	22228805
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 mRNA	23922739
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 protein	23922739
C006780	bisphenol A	bisphenol A affects the expression of ELAVL1 mRNA	21786754
C006780	bisphenol A	bisphenol A affects the expression of ELAVL1 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of ELAVL1 gene	28505145
D002084	Butylated Hydroxytoluene	Butylated Hydroxytoluene affects the localization of ELAVL1 protein	10900464
C026105	butylidenephthalide	butylidenephthalide results in decreased expression of ELAVL1 protein	23770345
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of ELAVL1 mRNA	31150632
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of ELAVL1 mRNA	23650126
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of ELAVL1 mRNA	27018022
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of ELAVL1 mRNA	19549813
D003471	Cuprizone	Cuprizone results in increased expression of ELAVL1 mRNA	26577399
D003513	Cycloheximide	Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]	25923732
D000077209	Decitabine	[Decitabine co-treated with trichostatin A] affects the localization of ELAVL1 protein	17891453
C007262	deoxynivalenol	[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein	22003189
C007262	deoxynivalenol	deoxynivalenol results in increased expression of and results in increased localization of ELAVL1 protein	19591856
C007262	deoxynivalenol	[deoxynivalenol results in increased expression of ELAVL1 protein] which results in decreased degradation of CXCL8 mRNA	19591856
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]	22003189
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA]	22003189
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]	19591856
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [deoxynivalenol results in increased expression of CXCL8 protein]	19591856
D003907	Dexamethasone	Dexamethasone results in increased expression of ELAVL1 mRNA	21804312
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of ELAVL1 mRNA	21266533
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of ELAVL1 mRNA	21266533
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene results in increased expression of ELAVL1 protein	21969073
D004147	Dioxins	Dioxins affects the expression of ELAVL1 mRNA	20463971
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELAVL1 mRNA	27188386
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ELAVL1 protein	23301498
C045651	epigallocatechin gallate	epigallocatechin gallate results in increased expression of ELAVL1 protein	31195006
D004958	Estradiol	Estradiol affects the expression of ELAVL1 mRNA	15598610
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of ELAVL1 mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ELAVL1 mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ELAVL1 mRNA	17942748
D005480	Flurbiprofen	ELAVL1 protein promotes the reaction [Flurbiprofen results in increased expression of NGFR protein]	18056468
D005480	Flurbiprofen	Flurbiprofen promotes the reaction [ELAVL1 protein binds to NGFR mRNA]	18056468
D005480	Flurbiprofen	Flurbiprofen results in increased expression of ELAVL1 protein	18056468
D019833	Genistein	Genistein results in decreased expression of ELAVL1 mRNA	22228119
D005839	Gentamicins	Gentamicins results in decreased expression of ELAVL1 mRNA	22061828
D007052	Ibuprofen	ELAVL1 protein promotes the reaction [Ibuprofen results in increased expression of NGFR protein]	18056468
D007052	Ibuprofen	Ibuprofen promotes the reaction [ELAVL1 protein binds to NGFR mRNA]	18056468
D007052	Ibuprofen	Ibuprofen results in increased expression of ELAVL1 protein	18056468
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ELAVL1 mRNA	25613284
C410337	K 7174	K 7174 results in decreased expression of ELAVL1 mRNA	24086573
D008070	Lipopolysaccharides	ELAVL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]	21391979
D008070	Lipopolysaccharides	ELAVL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]	21391979
D008627	Mercuric Chloride	Mercuric Chloride affects the expression of ELAVL1 mRNA	20353558
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of ELAVL1 protein	25809596
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in decreased expression of ELAVL1 mRNA	25554681
C051752	nefazodone	nefazodone results in increased expression of ELAVL1 mRNA	24136188
D009532	Nickel	Nickel results in decreased expression of ELAVL1 mRNA	25583101
D065108	Ornithine Decarboxylase Inhibitors	ELAVL1 protein promotes the reaction [Ornithine Decarboxylase Inhibitors inhibits the reaction [HNRNPD protein binds to JUND 3' UTR]]	20805360
D065108	Ornithine Decarboxylase Inhibitors	ELAVL1 protein promotes the reaction [Ornithine Decarboxylase Inhibitors promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]]	20805360
D065108	Ornithine Decarboxylase Inhibitors	ELAVL1 protein promotes the reaction [Ornithine Decarboxylase Inhibitors results in increased expression of JUND protein]	20805360
D065108	Ornithine Decarboxylase Inhibitors	ELAVL1 protein promotes the reaction [Ornithine Decarboxylase Inhibitors results in increased stability of JUND mRNA]	20805360
D065108	Ornithine Decarboxylase Inhibitors	Ornithine Decarboxylase Inhibitors affects the localization of ELAVL1 protein	20805360
D065108	Ornithine Decarboxylase Inhibitors	Ornithine Decarboxylase Inhibitors promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]	20805360
D065108	Ornithine Decarboxylase Inhibitors	[[Ornithine Decarboxylase Inhibitors results in decreased activity of ODC1 protein] which results in decreased chemical synthesis of Polyamines] promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]	20805360
D065108	Ornithine Decarboxylase Inhibitors	[[Ornithine Decarboxylase Inhibitors results in decreased activity of ODC1 protein] which results in decreased chemical synthesis of Polyamines] which affects the localization of ELAVL1 protein	20805360
D065108	Ornithine Decarboxylase Inhibitors	Putrescine inhibits the reaction [Ornithine Decarboxylase Inhibitors affects the localization of ELAVL1 protein]	20805360
D065108	Ornithine Decarboxylase Inhibitors	Putrescine inhibits the reaction [Ornithine Decarboxylase Inhibitors promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]]	20805360
D010269	Paraquat	Paraquat affects the localization of ELAVL1 protein	22879928
C006253	pirinixic acid	pirinixic acid results in decreased expression of ELAVL1 mRNA	18445702
C006253	pirinixic acid	pirinixic acid results in increased expression of ELAVL1 mRNA	18301758
D011073	Polyamines	[ODC1 protein results in increased chemical synthesis of Polyamines] inhibits the reaction [ELAVL1 protein binds to JUND 3' UTR]	20805360
D011073	Polyamines	[[Ornithine Decarboxylase Inhibitors results in decreased activity of ODC1 protein] which results in decreased chemical synthesis of Polyamines] promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]	20805360
D011073	Polyamines	[[Ornithine Decarboxylase Inhibitors results in decreased activity of ODC1 protein] which results in decreased chemical synthesis of Polyamines] which affects the localization of ELAVL1 protein	20805360
D011073	Polyamines	Polyamines deficiency promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]	20805360
D011700	Putrescine	Putrescine inhibits the reaction [Ornithine Decarboxylase Inhibitors affects the localization of ELAVL1 protein]	20805360
D011700	Putrescine	Putrescine inhibits the reaction [Ornithine Decarboxylase Inhibitors promotes the reaction [ELAVL1 protein binds to JUND 3' UTR]]	20805360
D000077185	Resveratrol	ELAVL1 mutant form inhibits the reaction [Resveratrol results in increased expression of MAT2B protein]	23814050
D000077185	Resveratrol	ELAVL1 mutant form inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]	23814050
D000077185	Resveratrol	MAT2B mutant form inhibits the reaction [Resveratrol results in increased expression of ELAVL1 protein]	23814050
D000077185	Resveratrol	Resveratrol promotes the reaction [ELAVL1 protein binds to MAT2B mRNA]	23814050
D000077185	Resveratrol	Resveratrol promotes the reaction [MAT2B protein binds to ELAVL1 protein]	23814050
D000077185	Resveratrol	Resveratrol results in increased expression of and results in increased stability of ELAVL1 protein	23814050
D000077185	Resveratrol	Resveratrol results in increased expression of ELAVL1 mRNA	23814050
D000077185	Resveratrol	SIRT1 mutant form inhibits the reaction [Resveratrol results in increased expression of ELAVL1 protein]	23814050
C085746	rottlerin	rottlerin inhibits the reaction [AGT protein affects the localization of ELAVL1 protein]	19246637
D012906	Smoke	Smoke affects the expression of ELAVL1 mRNA	23693141
C017947	sodium arsenite	Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]	25923732
C017947	sodium arsenite	EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]	25923732
C017947	sodium arsenite	ELAVL1 protein affects the reaction [sodium arsenite results in increased expression of RIPK2 mRNA modified form]	24865968
C017947	sodium arsenite	sodium arsenite affects the localization of ELAVL1 protein	22879928; 27932253;
C017947	sodium arsenite	sodium arsenite promotes the reaction [CHEK2 protein results in increased phosphorylation of ELAVL1 protein]	24865968
C017947	sodium arsenite	[sodium arsenite promotes the reaction [CHEK2 protein results in increased phosphorylation of ELAVL1 protein]] promotes the reaction [[ELAVL1 protein binds to TRA2B exon] which results in increased expression of TRA2B mRNA modified form]	24865968
C017947	sodium arsenite	sodium arsenite results in decreased expression of ELAVL1 protein	25923732
C017947	sodium arsenite	sodium arsenite results in increased phosphorylation of ELAVL1 protein	24865968
C017947	sodium arsenite	sodium arsenite promotes the reaction [ELAVL1 protein binds to TIA1 protein]	19765185
C017947	sodium arsenite	sodium arsenite promotes the reaction [ELAVL1 protein binds to TIAR protein]	19765185
D019810	Sodium Azide	Sodium Azide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]	12730239
D019810	Sodium Azide	Sodium Azide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR]	12730239
D019810	Sodium Azide	Sodium Azide results in decreased localization of ELAVL1 protein	12730239
D012999	Soman	Soman results in increased expression of ELAVL1 mRNA	19281266
D000077210	Sunitinib	Sunitinib results in increased expression of ELAVL1 mRNA	31533062
D013629	Tamoxifen	Tamoxifen affects the expression of ELAVL1 mRNA	17555576
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of ELAVL1 mRNA	15336504
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of ELAVL1 protein	19962423
D013749	Tetrachlorodibenzodioxin	U 0126 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELAVL1 protein]	19962423
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ELAVL1 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ELAVL1 mRNA	17942748
D013750	Tetrachloroethylene	Tetrachloroethylene results in decreased expression of ELAVL1 mRNA	28973375
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ELAVL1 mRNA	25613284
D014212	Tretinoin	Tretinoin results in decreased expression of ELAVL1 mRNA	23724009
C009524	tributyl phosphate	tributyl phosphate results in increased expression of ELAVL1 mRNA	27018022
C012589	trichostatin A	[Decitabine co-treated with trichostatin A] affects the localization of ELAVL1 protein	17891453
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELAVL1 mRNA	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of ELAVL1 mRNA	24935251; 26272509;
C013320	tris(2-butoxyethyl) phosphate	tris(2-butoxyethyl) phosphate results in decreased expression of ELAVL1 mRNA	27018022
C113580	U 0126	U 0126 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELAVL1 protein]	19962423
D014520	Urethane	Urethane affects the localization of ELAVL1 protein	10900464
D014520	Urethane	Urethane results in increased expression of ELAVL1 protein	10900464
D014635	Valproic Acid	Valproic Acid affects the expression of ELAVL1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of ELAVL1 mRNA	19101580
D014635	Valproic Acid	Valproic Acid results in increased expression of ELAVL1 mRNA	19101580; 23179753; 27188386;
D000068756	Valsartan	Valsartan inhibits the reaction [AGT protein affects the localization of ELAVL1 protein]	19246637
C025643	vinclozolin	vinclozolin affects the expression of ELAVL1 mRNA	19015723
D000077337	Vorinostat	Vorinostat results in decreased expression of ELAVL1 protein	22749963

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-1017	Isopeptide bond
KW-0488	Methylation
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0677	Repeat
KW-0694	RNA-binding
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR006548	ELAD_HU_SF
IPR034775	ELAV/Hu_RRM1
IPR002343	Hud_Sxl_RNA
IPR034996	HuR_RRM2
IPR012677	Nucleotide-bd_a/b_plait_sf
IPR035979	RBD_domain_sf
IPR000504	RRM_dom

PROSITE

PROSITE ID	PROSITE Term
PS50102	RRM

Pfam

Pfam ID	Pfam Term
PF00076	RRM_1

Gene: ELAVL1

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction